Stock comparison
GSK
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GSK
GSK
Market cap
$103.33B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GSK | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 75B | IDXX |
| Benjamin Graham | 62C | 80A | IDXX |
| Philip Fisher | 66B | 75B | IDXX |
| Peter Lynch | 47D | 71B | IDXX |
| Joel Greenblatt | 35D | 83C | IDXX |
| Charlie Munger | 65C | 87A | IDXX |
| Terry Smith | 63C | 84A | IDXX |
Side-by-side metrics
| Metric | GSK | IDXX |
|---|---|---|
| Market cap | $103.33B | $44.12B |
| P/E (TTM) | 12.9x | 39.0x |
| EV/EBIT | 10.8x | 31.6x |
| ROIC (TTM) | 13.76% | 40.66% |
| Gross margin | 72.74% | 62.05% |
| Net margin | 17.78% | 24.63% |
| Revenue CAGR 5y | 7.24% | 7.56% |
| EPS CAGR 5y | 19.78% | 10.79% |
| Debt / Equity | 1.1x | 0.7x |
| Dividend yield | 3.6% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GSK leads on
- Dividend yield3.6%vs 0.0%+100%
- P/E (TTM)12.9xvs 39.0x+67%
- EV/EBIT10.8xvs 31.6x+66%
- Market cap$103.33Bvs $44.12B+57%
IDXX leads on
- ROIC (TTM)40.66%vs 13.76%+66%
- Debt / Equity0.7xvs 1.1x+35%
- Net margin24.63%vs 17.78%+28%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.